Aurinia Pharmaceuticals annual r&d spending
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aurinia Pharmaceuticals R&D Spending Growth & History (AUPH)
Aurinia Pharmaceuticals's r&d spending was $32.5M for fiscal 2025.
View full Aurinia Pharmaceuticals company overviewAurinia Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $32.5M | $11.7M | +56.39% |
| 2024 | 2024-12-31 | $20.8M | −$28.9M | −58.13% |
| 2023 | 2023-12-31 | $49.6M | $4.7M | +10.34% |
| 2022 | 2022-12-31 | $45.0M | −$6.2M | −12.03% |
| 2021 | 2021-12-31 | $51.1M | $812,000 | +1.61% |
| 2020 | 2020-12-31 | $50.3M | −$2.5M | −4.80% |
| 2019 | 2019-12-31 | $52.9M | $11.5M | +27.75% |
| 2018 | 2018-12-31 | $41.4M | $7.5M | +21.96% |
| 2017 | 2017-12-31 | $33.9M | $19.4M | +133.45% |
| 2016 | 2016-12-31 | $14.5M | — | — |
Aurinia Pharmaceuticals quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.1M | $5.6M | +75.59% |
| Q1 2026 | 2026-03-31 | $7.5M | $1.7M | +30.07% |
| Q4 2025 | 2025-12-31 | $10.9M | $2.8M | +34.39% |
| Q3 2025 | 2025-09-30 | $8.4M | $5.4M | +176.83% |
| Q2 2025 | 2025-06-30 | $7.4M | $3.4M | +82.16% |
| Q1 2025 | 2025-03-31 | $5.7M | $192,000 | +3.46% |
| Q4 2024 | 2024-12-31 | $8.1M | −$2.1M | −20.74% |
| Q3 2024 | 2024-09-30 | $3.0M | −$10.6M | −77.60% |
| Q2 2024 | 2024-06-30 | $4.1M | −$8.6M | −67.75% |
| Q1 2024 | 2024-03-31 | $5.6M | −$7.6M | −57.81% |
| Q4 2023 | 2023-12-31 | $10.2M | $358,000 | +3.63% |
| Q3 2023 | 2023-09-30 | $13.6M | $2.6M | +23.99% |
| Q2 2023 | 2023-06-30 | $12.7M | $1.1M | +9.76% |
| Q1 2023 | 2023-03-31 | $13.2M | $538,000 | +4.26% |
| Q4 2022 | 2022-12-31 | $9.9M | −$1.3M | −11.47% |
| Q3 2022 | 2022-09-30 | $11.0M | −$9.1M | −45.32% |
| Q2 2022 | 2022-06-30 | $11.5M | $1.4M | +14.21% |
| Q1 2022 | 2022-03-31 | $12.6M | $2.8M | +28.34% |
| Q4 2021 | 2021-12-31 | $11.1M | −$2.0M | −15.36% |
| Q3 2021 | 2021-09-30 | $20.1M | $7.8M | +63.90% |
| Q2 2021 | 2021-06-30 | $10.1M | −$985,000 | −8.89% |
| Q1 2021 | 2021-03-31 | $9.8M | −$4.0M | −28.93% |
| Q4 2020 | 2020-12-31 | $13.2M | — | — |
| Q3 2020 | 2020-09-30 | $12.2M | — | — |
| Q2 2020 | 2020-06-30 | $11.1M | — | — |
| Q1 2020 | 2020-03-31 | $13.8M | — | — |
Aurinia Pharmaceuticals r&d spending trends
Over the last five fiscal years, Aurinia Pharmaceuticals's r&d spending decreased from $50.3M to $32.5M, a change of −$17.8M. The latest reported quarter, Q2 2026, shows $13.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aurinia Pharmaceuticals source filings ↗